Drew Pardoll
Founder at Potenza Therapeutics, Inc.
Profile
Drew M.
Pardoll was the founder of Amplimmune, Inc. (founded in 2007) where he served as Director from 2009 to 2011.
He is also the founder of Jounce Therapeutics, Inc. (founded in 2013) and Potenza Therapeutics, Inc. (founded in 2014) where he currently holds the title of Member-Scientific Advisory Board.
Dr. Pardoll is currently the Director at DNAtrix, Inc., The Sidney Kimmel Comprehensive Cancer Center, Dracen Pharmaceuticals, Inc., and The Johns Hopkins University.
He is also a Venture Partner at Catalio Capital Management LP.
Dr. Pardoll's former position includes being a member of the Scientific Advisory Board at Five Prime Therapeutics, Inc.Dr. Pardoll obtained his doctorate degree from The Johns Hopkins University.
Dr. Pardoll is also the founder of Tizona Therapeutics, Inc., Ervaxx Ltd...
Drew Pardoll active positions
Companies | Position | Start |
---|---|---|
The Johns Hopkins University | Corporate Officer/Principal | - |
The Sidney Kimmel Comprehensive Cancer Center
The Sidney Kimmel Comprehensive Cancer Center Hospital/Nursing ManagementHealth Services The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD. | Director/Board Member | 2009-08-27 |
Potenza Therapeutics, Inc.
Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Founder | 2013-12-31 |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Director/Board Member | - |
Dracen Pharmaceuticals, Inc.
Dracen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dracen Pharmaceuticals, Inc. develops immuno-metabolism drugs. The company was founded by Barbara Slusher, Jonathan D. Powell, Pavel Majer, and Rana Rais and is headquartered in New York, NY. | Director/Board Member | - |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Private Equity Investor | - |
Former positions of Drew Pardoll
Companies | Position | End |
---|---|---|
FIVE PRIME THERAPEUTICS, INC. | Consultant / Advisor | - |
Ervaxx Ltd.
Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Founder | - |
JOUNCE THERAPEUTICS, INC. | Founder | - |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Training of Drew Pardoll
The Johns Hopkins University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 10 |
---|---|
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Health Technology |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Technology |
Potenza Therapeutics, Inc.
Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Health Technology |
The Sidney Kimmel Comprehensive Cancer Center
The Sidney Kimmel Comprehensive Cancer Center Hospital/Nursing ManagementHealth Services The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD. | Health Services |
Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Dracen Pharmaceuticals, Inc.
Dracen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dracen Pharmaceuticals, Inc. develops immuno-metabolism drugs. The company was founded by Barbara Slusher, Jonathan D. Powell, Pavel Majer, and Rana Rais and is headquartered in New York, NY. | Health Technology |
Ervaxx Ltd.
Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Health Technology |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Finance |
- Stock Market
- Insiders
- Drew Pardoll